1. Home
  2. NRSN vs PFSA Comparison

NRSN vs PFSA Comparison

Compare NRSN & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRSN
  • PFSA
  • Stock Information
  • Founded
  • NRSN 2017
  • PFSA 2009
  • Country
  • NRSN Israel
  • PFSA United States
  • Employees
  • NRSN N/A
  • PFSA N/A
  • Industry
  • NRSN Biotechnology: Pharmaceutical Preparations
  • PFSA Medical/Dental Instruments
  • Sector
  • NRSN Health Care
  • PFSA Health Care
  • Exchange
  • NRSN Nasdaq
  • PFSA Nasdaq
  • Market Cap
  • NRSN 29.8M
  • PFSA 25.1M
  • IPO Year
  • NRSN 2021
  • PFSA N/A
  • Fundamental
  • Price
  • NRSN $1.18
  • PFSA $0.29
  • Analyst Decision
  • NRSN Buy
  • PFSA
  • Analyst Count
  • NRSN 2
  • PFSA 0
  • Target Price
  • NRSN $14.00
  • PFSA N/A
  • AVG Volume (30 Days)
  • NRSN 243.1K
  • PFSA 2.4M
  • Earning Date
  • NRSN 11-03-2025
  • PFSA 11-20-2025
  • Dividend Yield
  • NRSN N/A
  • PFSA N/A
  • EPS Growth
  • NRSN N/A
  • PFSA N/A
  • EPS
  • NRSN N/A
  • PFSA N/A
  • Revenue
  • NRSN N/A
  • PFSA $75,000.00
  • Revenue This Year
  • NRSN N/A
  • PFSA N/A
  • Revenue Next Year
  • NRSN N/A
  • PFSA N/A
  • P/E Ratio
  • NRSN N/A
  • PFSA N/A
  • Revenue Growth
  • NRSN N/A
  • PFSA 7.14
  • 52 Week Low
  • NRSN $0.80
  • PFSA $0.26
  • 52 Week High
  • NRSN $2.60
  • PFSA $5.50
  • Technical
  • Relative Strength Index (RSI)
  • NRSN 44.09
  • PFSA N/A
  • Support Level
  • NRSN $1.15
  • PFSA N/A
  • Resistance Level
  • NRSN $1.30
  • PFSA N/A
  • Average True Range (ATR)
  • NRSN 0.07
  • PFSA 0.00
  • MACD
  • NRSN -0.00
  • PFSA 0.00
  • Stochastic Oscillator
  • NRSN 31.43
  • PFSA 0.00

About NRSN NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

About PFSA Profusa Inc. Common Stock

Profusa Inc is a digital health technology company based in Emeryville, CA, that has developed a real-time, consumer-friendly platform that is designed to measure an individual's biochemistry, be easy to use, be cost-effective, and provide the necessary data to manage chronic disease and health and wellness decisions to improve health outcomes for a large population of potential users. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.

Share on Social Networks: